전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,016 programs
AntibodyLimited DatastaleRochePhase 2

adjuvant (Atezolizumab, Atezolizumab (adjuvant))

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

neoadjuvant (Atezolizumab, Atezolizumab (neoadjuvant))

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab + RP1)

Triple Negative Breast Neoplasms · Triple Negative Breast Neoplasms

#TripleNegativeBreastNeoplasms#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab combined with bevacizumab combined with β- alanine)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Preclinical

Auto CAR-T (Auto CAR-T)

Plasma Cell Tumors · Plasma Cell Tumors

#PlasmaCellTumors#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleChristian Medical College, Vell…Phase 1

Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene (Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene)

Hemophilia A · CD3

#CD3#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII (Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII)

Hemophilia A · CD3

#CD3#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleFred Hutchinson Cancer CenterPhase 1

Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 (Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143)

Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleAstraZenecaPhase 1

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014 (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014)

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Diffuse Large B-Cell Lymphoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Discontinued
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/CD19 dual-target CAR-T module (Autologous BCMA/CD19 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/CD38 dual-target CAR-T module (Autologous BCMA/CD38 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/GPRC5D dual-target CAR-T (Autologous BCMA/GPRC5D dual-target CAR-T)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleLuminary TherapeuticsPhase 1

Autologous CAR-T cell therapy expressing the BAFF-ligand. (Autologous CAR-T cell therapy expressing the BAFF-ligand.)

Multiple Myeloma, Refractory; Multiple Myeloma in Relapse · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleInstitute of Hematology and Blo…Phase 1

Autologous CAR123 T lymphocytes (Autologous CAR123 T lymphocytes)

Leukemia, Myeloid, Acute(AML); Precursor Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute(AML)

#LeukemiaMyeloidAcuteAML#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Autologous CCR4 CAR T cells (Autologous CCR4 CAR T cells)

Relapsed and/or Refractory Mature T Cell Malignancy; Peripheral T-Cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 1

Autologous CD19-targeting CAR T cells (Autologous CD19-targeting CAR T cells)

Acute Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD20 dual-target CAR-T module (Autologous CD19/CD20 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD22 dual-target CAR-T module (Autologous CD19/CD22 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleTessa TherapeuticsPhase 1

Autologous CD30.CAR-T (Autologous CD30.CAR-T)

Classical Hodgkin Lymphoma; Hodgkin Disease Refractory · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD33/CD123 dual-target CAR-T module (Autologous CD33/CD123 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

22 / 51 pages

← PreviousNext →